addiction Drugs to Treat Smoking Addiction Suggested by Multi-Ancestry Transcriptome-Wide Association Study The new approach, called TESLA, enables eQTL datasets to be integrated with multi-ancestry GWAS, which the researchers applied to study smoking behaviors. Proove Biosciences CEO Exonerated in PGx Test Kickback Case Proove's founder and CEO was indicted last year on charges the company had defrauded Medicare and violated the Anti-Kickback Statute by paying physicians to use its pharmacogenetic tests. Tobacco, Alcohol Use Contributors Uncovered With Multi-Ancestry GWAS Researchers unearthed more than 3,800 tobacco or alcohol use-related variants using data for 3.4 million participants from four ancestry groups. NIDA Awards Geisinger $973K to Study Genomics of Opioid Use Disorder Researchers will use data from two biobanks, Geisinger's MyCode Community Health Initiative and Vanderbilt University’s BioVU. IVitalize Acquires Genetic Testing Laboratory Geneus Health Geneus offers a genetic test to identify potential genetic predisposition to reward deficiency syndrome, a primary marker for addiction. Jan 15, 2019 Hundreds of Genetic Variants Implicated in Tobacco, Alcohol Use Jun 6, 2018 FDA Grants Breakthrough Designation for AutoGenomics' Infiniti Neural Response Panel Jan 18, 2018 AACC Drug Testing Guidelines Take Steps Toward Reducing Excessive Drug Panel Testing Oct 9, 2017 U of Michigan Precision Health Effort Looking Beyond Genomics in Researching Opioid Crisis Premium Aug 29, 2017 Prescient Medicine Launches Addiction Risk Test Developed With AutoGenomics Premium Jan 11, 2017 NIH to Fund Research Into Genetics of Drug Addiction Aug 10, 2016 Jackson Lab Receives $11.7 Million NIH Grant to Study Neurogenetics of Addiction Jul 18, 2016 Proove Biosciences Building Opioid PGx Test Evidence; Experts Question Available Data Premium Mar 30, 2016 GWAS Identifies Loci Linked to Cannabis Dependence Dec 6, 2013 NIDA to Fund Studies of Genes, Variants Involved in Addiction Nov 25, 2013 NIDA to Fund Addiction-related Gene Studies in Animal Models Jan 9, 2013 Dominion Diagnostics, LifeGen Conducting Validation Trial of Genomic Test for Addiction Risk Premium Dec 17, 2012 Dominion Diagnostics Licenses Rights to LifeGen Genetic Test Technology Aug 31, 2012 GW, Maryland Use NIDA Funds to Find Addiction Genes Jun 11, 2012 NIDA Wants Education Programs to Use Genetic Data in Addiction Research Apr 2, 2012 NIDA to Prioritize Addiction Genetics Research Funding Jan 19, 2011 Drug Abuse Institute Seeks PGx Proposals Premium Nov 19, 2010 NIH to Provide Grants for Addiction Genomics Research Mar 25, 2009 Genetically Stratifying Smoking-Cessation Trials Could Save Up to $15M, Researchers Find Premium Breaking News FDA Grants Marketing Authorization for Invitae Hereditary Cancer DNA Sequencing Test Compact Gene Editing Enzyme May Improve Success Rates of Gene Therapies People in the News at Veracyte, Invitae, Mount Sinai, InterVenn Biosciences, Applied BioCode, More New Products Posted to GenomeWeb: Qiagen, IDT, Revvity, Mission Bio, NRichDx, More FDA Releases Proposed Rule for Oversight of Laboratory-Developed Tests The Scan Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants. Small Study of Gene Editing to Treat Sickle Cell Disease In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms. Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema. Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.